Nonsteroidal Anti-inflammatory Drug
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Nonsteroidal Anti-inflammatory Drug
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) represent a cornerstone therapy for managing pain and inflammation by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis. This mechanism underpins their efficacy in a wide array of conditions, from acute pain to chronic inflammatory diseases. The therapeutic landscape for NSAIDs is extensive, with early approvals like PERCODAN (aspirin) in 1950 by ENDO OPERATIONS setting the stage for a class that would become ubiquitous in pain management. Subsequent innovations introduced drugs targeting specific COX isoforms or offering improved pharmacokinetic profiles, broadening their clinical utility.
Approved NSAIDs span a range of indications, including rheumatoid arthritis, osteoarthritis, and various pain states. Drugs such as NAPROSYN (naproxen), first approved in 1976 by ATNAHS PHARMA US, and FELDENE (piroxicam) in 1982 by Pfizer, became mainstays for chronic inflammatory conditions. More selective agents like CELEBREX (celecoxib), approved in 1998 by UPJOHN, aimed to reduce gastrointestinal side effects associated with non-selective NSAIDs. The evolution continues with newer formulations and delivery methods, such as NEVANAC (nepafenac) and ILEVRO (nepafenac) for ocular pain and inflammation, and CALDOLOR (ibuprofen) for perioperative pain and fever.
The field is continuously evolving, with ongoing research exploring novel applications and delivery systems to enhance efficacy and safety. While established NSAIDs remain critical, the focus is shifting towards precision medicine, identifying patient populations most likely to benefit and those at highest risk of adverse events. The development of new chemical entities and advanced formulations aims to address unmet needs and refine the therapeutic profile of this essential drug class, ensuring its continued relevance in modern medicine.
36 FDA-approved Nonsteroidal Anti-inflammatory Drug drugs, including CALDOLOR, with 73 active Phase 3 trials across 8 indications from 10 active sponsors. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Nonsteroidal Anti-inflammatory Drug Drugs
36 totalNonsteroidal Anti-inflammatory Drugs have a rich history, originating with the broad-acting aspirin, PERCODAN, introduced by ENDO OPERATIONS in 1950. This marked the dawn of a class that would revolutionize pain and inflammation management. Early evolution saw the introduction of drugs like PONSTEL (mefenamic acid) in 1967 and NAPROSYN (naproxen) in 1976, offering different profiles and durations of action. The development of selective COX-2 inhibitors, exemplified by CELEBREX (celecoxib) in 1998, represented a significant advancement, aiming to mitigate the gastrointestinal risks associated with traditional NSAIDs while retaining efficacy. Individual Nonsteroidal Anti-inflammatory Drugs differentiate themselves through various factors, including COX selectivity, efficacy in specific indications, and pharmacokinetic properties. For instance, naproxen, available as NAPROSYN and EC-NAPROSYN, offers a longer half-life suitable for chronic conditions, while ibuprofen, seen in CALDOLOR, provides rapid pain and fever relief. Celecoxib, both in CELEBREX and ELYXYB, targets COX-2 selectively, aiming for improved gastrointestinal safety. Ocular NSAIDs like NEVANAC and ILEVRO demonstrate the class's adaptability to specialized delivery and indications. Today, Nonsteroidal Anti-inflammatory Drugs occupy a critical position in the therapeutic armamentarium, often serving as first-line agents for pain and inflammation. While generic competition is robust for many older NSAIDs, newer formulations and selective agents continue to find their niche. The class-wide understanding of cardiovascular and gastrointestinal risks influences their positioning, particularly in patients with pre-existing comorbidities. Despite the emergence of biologics and other novel therapies, NSAIDs remain indispensable for their broad applicability, cost-effectiveness, and established efficacy in managing a wide spectrum of inflammatory and painful conditions.
+12 more (biosimilars and reformulations not shown). ★ = originator.
Nonsteroidal Anti-inflammatory Drug Indications in Trials
Active industry trialsThe current pipeline activity for Nonsteroidal Anti-inflammatory Drugs shows a notable concentration in metabolic indications, with obesity and overweight leading the charge with three and two active trials respectively. The indication 'Overweight and/or Obesity' also contributes one active trial, suggesting a significant focus on addressing these prevalent conditions. Beyond metabolic health, there is emerging interest in autoimmune and oncological indications, with single active trials in Primary Membranous Nephropathy, Plasma Cell Myeloma Refractory, and Lupus Nephritis, indicating a potential expansion of the NSAID therapeutic scope. This pipeline activity signals an expansion frontier beyond the traditional pain and inflammation space. The focus on obesity and overweight suggests novel therapeutic hypotheses, potentially leveraging the anti-inflammatory properties of NSAIDs to address the underlying inflammatory components of these conditions. The exploration in nephrology and oncology indicates a search for new patient subpopulations or disease contexts where NSAIDs might offer unique benefits, possibly in combination therapies or as adjunct treatments. The data does not specify modality trends, but the continued presence of oral NSAIDs in development is expected. Looking ahead to the next 6-12 months, key readouts from trials in obesity and overweight will be critical for understanding the viability of NSAIDs in these areas. The limited activity in other novel indications suggests that while exploration is occurring, these remain nascent frontiers. The pipeline appears moderately active, with a clear emphasis on metabolic disorders. The thinning of the pipeline in traditional inflammatory diseases may indicate a saturation of innovation or a shift towards more targeted therapies, but the expansion into metabolic and other areas suggests ongoing strategic interest in leveraging NSAID mechanisms.
Top Nonsteroidal Anti-inflammatory Drug Sponsors
Industry trials, any indicationSanofi is the dominant player in the current Nonsteroidal Anti-inflammatory Drug landscape, leading with three active trials. This leadership likely stems from a strategic focus on leveraging NSAID mechanisms within their broader therapeutic areas, potentially exploring novel applications or formulations that align with their existing portfolio and research strengths. Their significant trial count suggests a deep commitment to advancing NSAID-based therapies, possibly building on established franchises or exploring new therapeutic hypotheses. Key challengers include Hoffmann-La Roche and Laboratorios Silanes S.A. de C.V., each with two active trials. These sponsors are actively competing across various indications, indicating a broad interest in the NSAID space. Pfizer, with one active trial, also remains a notable participant. The competition appears to be driven by both established players seeking to innovate within their existing drug classes and potentially by companies aiming to develop next-generation NSAIDs or repurpose existing ones for new indications. The strategic landscape for Nonsteroidal Anti-inflammatory Drug development shows a mix of established pharmaceutical giants and specialized companies. The geographic focus of these trials is not explicitly detailed, but the presence of multiple sponsors suggests a global interest. Upcoming catalysts could include positive data readouts from the leading sponsors, particularly in the high-activity metabolic indications. For investors and business development scouts, this indicates a dynamic field with opportunities for both incremental innovation and potentially disruptive new applications of NSAID pharmacology, especially as companies seek to address unmet needs in metabolic and inflammatory diseases.
Nonsteroidal Anti-inflammatory Drug Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved Nonsteroidal Anti-inflammatory Drug drugs across 3 indications from 3 sponsors. Earliest readout: Q2 2024.
Coverage: trials whose intervention is an approved Nonsteroidal Anti-inflammatory Drug drug. Pre-approval candidates with development codes are not yet linked.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.